Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management

Journal of Basic and Clinical Physiology and Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Abstract Incretin-based medicines have considerably impacted the treatment of type 2 diabetes mellitus (T2DM), providing considerable advantages in glycemic regulation, weight control, and cardiovascular results. This narrative review examines progress incretin medicines, encompassing glucagon-like peptide-1 (GLP-1) receptor agonists, dual-receptor, triple-receptor while emphasizing their therapeutic advantages, obstacles, prospective developments. The examined articles were sourced from databases including PubMed Google Scholar, concentrating on publications predominantly 2010 to 2024. Selective foundational papers released before this timeline incorporated furnish critical historical context about processes discovery. despite efficacy, encounter hurdles elevated costs, patient compliance difficulties, variability response attributable genetic physiological variables. Moreover, there are still deficiencies comprehending long-term safety cancer risks linked these medicines. Emerging dual- agonists demonstrate potential overcoming shortcomings conventional GLP-1 enhanced metabolic results broader uses intricate disease profiles. Future research must concentrate economic streamlined regimens, customized medicine, integration artificial intelligence, stratification, as well efficacy incretin-based for holistic management T2DM.

Language: Английский

Yerba Mate (Ilex paraguariensis St. Hill.) Tea May Have Cardiometabolic Beneficial Effects in Healthy and At‐Risk Subjects: A Randomized, Controlled, Blind, Crossover Trial in Nonhabitual Consumers

Molecular Nutrition & Food Research, Journal Year: 2025, Volume and Issue: unknown

Published: April 22, 2025

ABSTRACT Yerba mate has been reported to have antihypertensive, hypocholesterolemic, antidiabetic, or antiobesity properties. Most evidences from human trials involved intakes of high amounts by habitual consumers. Considering its increasing popularity, this study aimed at assessing the potential cardiometabolic effects moderate intake yerba nonhabitual A randomized, crossover, controlled was carried out in healthy and hypercholesterolemic subjects. Anthropometric parameters, blood pressure, lipids, glucose metabolism, inflammatory cytokines, chemokines, different markers endothelial function, as well incretins, adipocytokines, hormones were measured baseline after 8 weeks consuming a decaffeinated isotonic drink (control). After daily consumption three servings tea, colony‐stimulating factors decreased all participants. LDL‐C normocholesterolemic individuals, while control interventions elicited similar hypolipidemic action group. Ghrelin glucose‐dependent insulinotropic polypeptide (GIP) significantly intake, glucagon‐like peptide 1 (GLP‐1) adipocytokines remained unchanged. Body fat percentage tricipital skinfold only subjects, with no on total body weight. In conclusion, could exert protective consumers subjects cardiovascular risk. Trial Registration : This trial retrospectively registered ClinicalTrials (NCT06729905)

Language: Английский

Repurposing glucose-lowering drugs for cancer therapy

Trends in cancer, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

The acknowledged relationship between metabolism and cancer retains important potential as a novel target in therapy. Reallocating glucose-lowering drugs (GLDs) treatment offers valuable perspectives for the ability of these molecules to regulate at cellular systemic level. This comprehensive review addresses therapeutic main antidiabetic classes with emerging anticancer effects, such metformin, rosiglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium/glucose cotransporter-2 inhibitors. multifaceted actions are explored, from vitro evidence clinical monotherapy or sparing agent chemotherapy immunotherapy. For each molecule, unconventional mechanisms, benefits, limitations dissected possible concerns addressed, supporting use drug cancer.

Language: Английский